Liquid grafts engineered for lasting therapy
Embedded Files
We engineer a patient’s own skin cells for the durable production of therapeutic proteins
RDEB: Recessive Dystrophic
Epidermolysis Bullosa
Our first indication is also known as "the butterfly disease" because patients' skin is as fragile as a butterfly's wing
Cause: Defects in COL7A1 lead to a lack of anchoring fibrils that hold layers of skin together.
Pathology: Any friction causes the skin to blister and shear, leading to painful wounds, a 90% increase in skin cancer risk, and early death
Our platform was shown to be safe and effective in human RDEB patients through an investigator-initiated trial
With competitive advantages in durable efficacy, manufacturing simplicity, and ease of application over all other clinical-stage RDEB therapies, our lean team is excited to bring a best in class option to RDEB patients.
Please reach out to info@addgraft.com to learn more.
Page updated
Report abuse